Platelet and endothelial response with trapidil in patients with peripheral obliterative arteriopathy.
The activity of trapidil, an antiaggregating agent with PDGF antagonist properties, was investigated in order to verify its possible modulating effect in the endothelial and platelet activation. PDGF, t-PA, PAI-1 and ET-1 plasma levels were measured before and after a 2 month treatment period with trapidil 200 mg tablets bid or placebo in 30 patients affected by POA in Fontaine stage II. PDGF and PAI-1 significantly (p < 0.05) increased in the placebo group, and PDGF also in the comparison between treatments (p < 0.05). Aggregation data demonstrate an absence of Ca++ antagonist action of trapidil. The results of this study suggest that trapidil can interfere with the combined vascular and platelet response in atherogenesis.
Bonfardeci
G
G
San Carlo Borromeo General Hospital, Milan, Italy.
Cimminiello
C
C
Cantini
L
L
Arpaia
G
G
Aloisio
M
M
Pozzi
F
F
D000368:Aged; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy*; D001792:Blood Platelets / Q000187:drug effects; D004311:Double-Blind Method; D016232:Endothelins / Q000097:blood; D004730:Endothelium, Vascular / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D016491:Peripheral Vascular Diseases / Q000097:blood / Q000188:drug therapy*; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010982:Platelet-Derived Growth Factor / Q000032:analysis; D010959:Tissue Plasminogen Activator / Q000097:blood; D014192:Trapidil / Q000627:therapeutic use*
D016232:Endothelins; D017395:Plasminogen Activator Inhibitor 1; D010975:Platelet Aggregation Inhibitors; D010982:Platelet-Derived Growth Factor; D010959:Tissue Plasminogen Activator; D014192:Trapidil